Who is sponsoring NCT00081237?

NCT00081237 is sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

What condition does NCT00081237 study?

NCT00081237 studies Colorectal Cancer.

What drugs are being tested in NCT00081237?

Interventions: OSI-7904L, oxaliplatin.

What is the status of NCT00081237?

NCT00081237 is currently COMPLETED.

Last reviewed 2013-06-11 · How we verify

A Phase I Study of OSI-7904L In Combination With Oxaliplatin In Patients With Advanced Colo-Rectal Cancer

NCT00081237 Phase 1 COMPLETED

RATIONALE: OSI-7904L may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining OSI-7904L with oxaliplatin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of OSI-7904L and oxaliplatin in treating patients with refractory or recurrent advanced colorectal cancer.

Details

Lead sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Phase	Phase 1
Status	COMPLETED
Enrolment	15
Start date	2004-02

Conditions

Colorectal Cancer

Interventions

OSI-7904L
oxaliplatin

Primary outcomes

Maximum tolerated dose and recommended dose for future trials as measured by CTC v3.0

Countries

Germany, United Kingdom